ACET Key Statistics, Chart & Performance
The current stock price of ACET is 0.5229 USD. In the past month the price decreased by -21.07%. In the past year, price decreased by -49.12%.
ACET Latest News, Press Relases and Analysis
ACET Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.81 | 397.68B | ||
| AMGN | AMGEN INC | 14.93 | 175.87B | ||
| GILD | GILEAD SCIENCES INC | 14.82 | 150.63B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.13 | 115.10B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.89 | 75.18B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 874.94 | 58.95B | ||
| INSM | INSMED INC | N/A | 43.92B | ||
| NTRA | NATERA INC | N/A | 33.88B | ||
| BIIB | BIOGEN INC | 10.83 | 26.60B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.34 | 20.84B | ||
| INCY | INCYTE CORP | 15.32 | 19.31B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.20B |
Related stock screener links
About ACET
Company Profile
Adicet Bio, Inc. is a clinical stage biotechnology company, which engages in discovering and developing allogeneic gamma delta T cell therapies for cancer. The company is headquartered in Boston, Massachusetts and currently employs 152 full-time employees. The company went IPO on 2018-01-26. The company is engaged in advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. Its lead product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases. ADI-001 contains an anti-CD20 CAR that has a proprietary antigen-binding domain that recognizes a region of CD20 distinct from that recognized by rituximab. Its pipeline also includes ADI-270, an investigational allogeneic gamma delta CAR T cell therapy targeting CD70 via the CD27-ligand for the treatment of RCC and with potential in other solid tumor and hematological malignancy indications. Its pipeline has additional internal gamma delta T cell therapy programs in discovery and preclinical development for both hematological malignancies and solid tumors.
Company Info
ADICET BIO INC
131 Dartmouth Street, 3Rd Floor
Boston MASSACHUSETTS 02116 US
CEO: Chen Schor
Employees: 152
Phone: 16174822333
ADICET BIO INC / ACET FAQ
What does ACET do?
Adicet Bio, Inc. is a clinical stage biotechnology company, which engages in discovering and developing allogeneic gamma delta T cell therapies for cancer. The company is headquartered in Boston, Massachusetts and currently employs 152 full-time employees. The company went IPO on 2018-01-26. The company is engaged in advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. Its lead product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases. ADI-001 contains an anti-CD20 CAR that has a proprietary antigen-binding domain that recognizes a region of CD20 distinct from that recognized by rituximab. Its pipeline also includes ADI-270, an investigational allogeneic gamma delta CAR T cell therapy targeting CD70 via the CD27-ligand for the treatment of RCC and with potential in other solid tumor and hematological malignancy indications. Its pipeline has additional internal gamma delta T cell therapy programs in discovery and preclinical development for both hematological malignancies and solid tumors.
What is the stock price of ADICET BIO INC today?
The current stock price of ACET is 0.5229 USD. The price decreased by -2.12% in the last trading session.
What is the dividend status of ADICET BIO INC?
ACET does not pay a dividend.
What is the ChartMill rating of ADICET BIO INC stock?
ACET has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Where is ADICET BIO INC (ACET) stock traded?
ACET stock is listed on the Nasdaq exchange.
What is the analyst forecast for ACET stock?
14 analysts have analysed ACET and the average price target is 7.75 USD. This implies a price increase of 1382.5% is expected in the next year compared to the current price of 0.5229.
When does ADICET BIO INC (ACET) report earnings?
ADICET BIO INC (ACET) will report earnings on 2026-03-04, after the market close.
ACET Technical Analysis
ACET Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ACET. While ACET seems to be doing ok healthwise, there are quite some concerns on its profitability.
ACET Financial Highlights
Over the last trailing twelve months ACET reported a non-GAAP Earnings per Share(EPS) of -1.26. The EPS increased by 26.32% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -72.53% | ||
| ROE | -88.63% | ||
| Debt/Equity | 0 |
ACET Forecast & Estimates
14 analysts have analysed ACET and the average price target is 7.75 USD. This implies a price increase of 1382.5% is expected in the next year compared to the current price of 0.5229.